Marica Orioli

Prof. Marica Orioli

Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Università degli Studi di Milano
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2005 in Analytica Chimica Acta
Verified
Journal Article
Closed access
GBGiangiacomo Beretta
Giangiacomo Beretta
PGPaola Granata
Paola Granata
MFMaria Ferrero
Maria Ferrero
Marica OrioliMarica Orioli
Marica Orioli
RFRoberto Maffei Facino
Roberto Maffei Facino

30 May 2011 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
Giancarlo AldiniGiancarlo Aldini
Giancarlo Aldini
Marica OrioliMarica Orioli
Marica Orioli
GRGiuseppe Rossoni
Giuseppe Rossoni
FSFederica Savi
Federica Savi
PBPaola Braidotti
Paola Braidotti
MCMarina Carini
Marina Carini
The metabolic syndrome is a risk factor that increases the risk for development of renal and vascular complications. This study addresses the effects of chronic administration of the endogenous dipeptide carnosine (β‐alanyl‐L‐histidine, L‐CAR) and of its enantiomer (β‐alanyl‐D‐histidine, D‐CAR) on hyperlipidaemia, hypertension, advanced glycation end products, advanced lipoxidation end products formation and development of nephropathy in the non‐diabetic, Zucker obese rat. The Zucker rats received a daily dose of L‐CAR or D‐CAR (30 mg/kg in drinking water) for 24 weeks. Systolic blood pressure was recorded monthly. At the end of the treatment, plasma levels of triglycerides, total cholesterol, glucose, insulin, creatinine and urinary levels of total protein, albumin and creatinine were measured. Several indices of oxidative/carbonyl stress were also measured in plasma, urine and renal tissue. We found that both L‐ and D‐CAR greatly reduced obese‐related diseases in obese Zucker rat, by significantly restraining the development of dyslipidaemia, hypertension and renal injury, as demonstrated by both urinary parameters and electron microscopy examinations of renal tissue. Because the protective effect elicited by L‐ and D‐CAR was almost superimposable, we conclude that the pharmacological action of L‐CAR is not due to a pro‐histaminic effect (D‐CAR is not a precursor of histidine, since it is stable to peptidic hydrolysis), and prompted us to propose that some of the biological effects can be mediated by a direct carbonyl quenching mechanism.

3 August 2006 in Journal of Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
Giancarlo AldiniGiancarlo Aldini
Giancarlo Aldini
LGLuca Gamberoni
Luca Gamberoni
Marica OrioliMarica Orioli
Marica Orioli
GBGiangiacomo Beretta
Giangiacomo Beretta
LRLuca Regazzoni
Luca Regazzoni
MCMarina Carini
Marina Carini

19 April 2009 in Amino Acids
Verified
Journal Article
Closed access
PDF file
KYKyung-Jin Yeum
Kyung-Jin Yeum
Marica OrioliMarica Orioli
Marica Orioli
LRLuca Regazzoni
Luca Regazzoni
MCMarina Carini
Marina Carini
HRHelen Rasmussen
Helen Rasmussen
Giancarlo AldiniGiancarlo Aldini
Giancarlo Aldini

1 August 2011 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
Giancarlo AldiniGiancarlo Aldini
Giancarlo Aldini
Marica OrioliMarica Orioli
Marica Orioli
MCMarina Carini
Marina Carini

9 January 2012 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
Stefano MeniniStefano Menini
Stefano Menini
CICarla Iacobini
Carla Iacobini
CRCarlo Ricci
Carlo Ricci
ASAngela Scipioni
Angela Scipioni
CFClaudia Blasetti Fantauzzi
Claudia Blasetti Fantauzzi
Giuseppe PuglieseGiuseppe Pugliese
Giuseppe Pugliese
BACKGROUND AND PURPOSE Lipoxidation‐derived reactive carbonyl species (RCS) such as 4‐hydroxy‐2‐nonenal (HNE) react with proteins to form advanced lipoxidation end products (ALEs), which have been implicated in both atherosclerosis and renal disease. L‐carnosine acts as an endogenous HNE scavenger, but it is rapidly inactivated by carnosinase. This study aimed at assessing the effect of the carnosinase‐resistant, D‐carnosine, on HNE‐induced cellular injury and of its bioavailable prodrug D‐carnosine octylester on experimental atherosclerosis and renal disease.EXPERIMENTAL APPROACH Vascular smooth muscle cells (VSMCs) were exposed to HNE or H2O2 plus D‐carnosine. ApoE null mice fed a Western, pro‐atherogenic diet were treated with D‐carnosine octylester for 12 weeks.KEY RESULTS In vitro, D‐carnosine attenuated the effect of HNE, but not of H2O2, on VSMCs. In vivo, D‐carnosine octylester‐treated mice showed reduced lesion area and a more stable plaque phenotype compared with untreated animals, with reduced foam cell accumulation, inflammation and apoptosis and increased clearance of apoptotic bodies and collagen deposition, resulting in decreased necrotic core formation. Likewise, renal lesions were attenuated in D‐carnosine octylester‐treated versus untreated mice, with lower inflammation, apoptosis and fibrosis. This was associated with increased urinary levels of HNE‐carnosine adducts and reduced protein carbonylation, circulating and tissue ALEs, expression of receptors for these products, and systemic and tissue oxidative stress.CONCLUSIONS AND IMPLICATIONS These data indicate RCS quenching with a D‐carnosine ester was highly effective in attenuating experimental atherosclerosis and renal disease by reducing carbonyl stress and inflammation and that this may represent a promising therapeutic strategy in humans.